US FDA approves Reata Pharmaceuticals’ SKYCLARYS for Friedreich’s ataxia
Pharmaceutical Technology
MARCH 2, 2023
SKYCLARYS is the first approved treatment in Friedrich’s Ataxia and marks a milestone for drug development in this complex disease. There are three more drug candidates with major trial readouts that are expected in 2023. The FDA granted Orphan Drug, Fast Track, and Rare Pediatric Disease Designations for the medication.
Let's personalize your content